Shanghai, China, February 07, 2024 — MicroPort®

中国上海，2024年2月7日-MicroPort®

CRM’s latest generation transvenous MR-conditional safe implantable pacemaker system has obtained approval in China.

CRM最新一代经静脉MR条件性安全植入式起搏器系统已在中国获得批准。

The ENO™ pacemaker family, including ENO™, TEO™, and OTO™, features a compact volume of only 8cc and a projected longevity of up to 12 years. Comprising the ENO™ pacemaker and Vega™ pacing leads available in 3 lengths for clinical flexibility, this system is compatible with 1.5T/3T full-body MRI scans.

ENO™起搏器系列，包括ENO™、TEO™和OTO™，体积紧凑，只有8cc，预计寿命长达12年。该系统由ENO™起搏器和Vega™起搏导线组成，具有3种长度，可用于临床灵活性，可与1.5T/3T全身MRI扫描兼容。

.

.

Featuring an AutoMRI™ mode, the ENO™ increases patients’ safety and quality of life when undergoing an MRI examination. The pacemaker automatically switches to activate the MRI mode upon entering the MRI field and reverts to its initial settings following the exam. This technology allows patients to have repeated MRI scans within 10 days without further intervention, significantly improving workflow for both patients and medical staff..

ENO™具有AutoMRI™模式，可在接受MRI检查时提高患者的安全性和生活质量。起搏器在进入MRI区域后自动切换以激活MRI模式，并在检查后恢复到其初始设置。该技术允许患者在10天内重复进行MRI扫描，无需进一步干预，从而显着改善了患者和医务人员的工作流程。。

As part of the “Clinical Investigation of ENO/TEO/OTO Pacing System (CAPRI) study conducted in 29 clinical centers worldwide, the ENO™ system’s safety and efficacy under MRI conditions was demonstrated . The research findings were published in the authoritative journal “European Radiology “ in 2023.

作为在全球29个临床中心进行的“ENO/TEO/OTO起搏系统（CAPRI）临床研究”的一部分，证明了ENO™系统在MRI条件下的安全性和有效性。研究结果于2023年发表在权威期刊“欧洲放射学”上。

1.

1.

About MicroPort® CRM

关于MicroPort®CRM

MicroPort®

微孔®

CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM) with global headquarters in Clamart, near Paris, France and an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853). Through its long-standing expertise in CRM, MicroPort® CRM develops, manufactures and commercializes cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure, globally.

CRM是心律管理（CRM）领域的先驱公司，全球总部位于法国巴黎附近的Clamart，是MicroPort®（MicroPort Scientific Corporation；HKEX:00853）的关联公司。凭借其在CRM方面的长期专业知识，MicroPort®CRM在全球范围内开发、制造和商业化心脏起搏器、植入式心脏除颤器、心脏再同步系统和ECG诊断解决方案，用于管理心律失常和心力衰竭。

These state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic. MicroPort® CRM also distributes MicroPort® solutions in Interventional Cardiology and Electrophysiology in Europe..

这些最先进的产品在法国的Clamart、意大利的Saluggia和多米尼加共和国的圣多明各制造。MicroPort®CRM还在欧洲的介入心脏病学和电生理学领域分销MicroPort®解决方案。。

More information is available at www.microport.com.

有关更多信息，请访问www.microport.com。

Reference:

参考号：

1：Dacher JN, Langguth P, Adam D, Winkler WB, Martí-Almor J, Prenner G, et al. Safety and performance of MR-conditional pacing systems with automated MRI mode at 1.5 and 3 Tesla. Eur Radiol 2023;33(10):6948-58.

1： Dacher JN，Langguth P，Adam D，Winkler WB，Martí-Almor J，Prenner G等。在1.5和3特斯拉的自动MRI模式下MR条件性起搏系统的安全性和性能。Eur Radio 2023；33（10）：6948-58。